Spherix Introduces Patient Chart Dynamix™, an Enhanced
Exton, PA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights, a trusted leader in pharmaceutical market research, is delighted to announce the...
Stay updated with breaking news from Systemic Lupus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exton, PA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights, a trusted leader in pharmaceutical market research, is delighted to announce the...
21.07.2023 - Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2 clinical trial evaluating daxdilimab for the treatment of SLE did not show a statistically significant separation between daxdilimab and placebo on the primary endpoint, which ...
Global Systemic Lupus Erythematosus Market is valued at approximately USD $ million in 2021 and is anticipated to grow with a healthy growth rate of m
INSIDE INFORMATION Agreement with the main creditors of BioSenic for a standstill running until October 2023 Mont-Saint-Guibert, Belgium, July 10th, 2023, 7.00 am CEST – BIOSENIC ,...
INSIDE INFORMATION Launch of negotiation with main creditors Agreement with Global Tech Opportunities (GTO) to secure short term financing Mont-Saint-Guibert, Belgium, June 30, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the innovative company addressing unmet medical needs in the areas of innate immunity, inflammation and organ/function repair, today provides a financial update. BioSenic has obtained an official appointment of Yves Brulard to reach a negotiated agreement